David S Rickman

List of Publications by Year
in descending order

29 papers	3,260 citations	394421 19 h-index	552781 26 g-index
29 all docs	29 docs citations	29 times ranked	5292 citing authors

#	Article	IF	Citations
1	Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Advanced Materials, 2022, 34, e2100096.	21.0	24
2	Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022). Advanced Materials, 2022, 34, .	21.0	0
3	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 44.	5.4	20
4	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nature Communications, 2021, 12, 3372.	12.8	45
5	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Research, 2021, 81, 4736-4750.	0.9	18
6	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
7	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Neoplasia, 2019, 21, 389-400.	5.3	20
8	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	105
9	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51.	7.0	177
10	N-Mycâ€“mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. Journal of Clinical Investigation, 2019, 129, 3924-3940.	8.2	115
11	Immunogenomic landscape of neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2019, 37, 224-224.	1.6	1
12	The Expanding World of N-MYCâ€“Driven Tumors. Cancer Discovery, 2018, 8, 150-163.	9.4	170
13	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. Blood, 2018, 132, 1435-1435.	1.4	1
14	Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. Cell Reports, 2017, 21, 3483-3497.	6.4	71
15	Biology and evolution of poorly differentiated neuroendocrine tumors. Nature Medicine, 2017, 23, 664-673.	30.7	192
16	Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome Biology, 2017, 18, 141.	8.8	31
17	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 30, 563-577.	16.8	394
18	A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. Cell Reports, 2016, 15, 2348-2356.	6.4	29

#	Article	IF	Citations
19	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncology, 2015, 1, 466.	7.1	264
20	Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. Journal of Clinical Oncology, 2015, 33, 158-158.	1.6	1
21	Abstract PR08: The N-Myc transcriptional program driving the neuroendocrine prostate cancer phenotype. , 2015, , .		0
22	Aggressive Variants of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 2846-2850.	7.0	339
23	ERG induces taxane resistance in castration-resistant prostate cancer. Nature Communications, 2014, 5, 5548.	12.8	96
24	Oncogene-mediated alterations in chromatin conformation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9083-9088.	7.1	142
25	Oncogenic transcription factors as master regulators of chromatin topology. Cell Cycle, 2012, 11, 3380-3383.	2.6	14
26	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	9.4	725
27	ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. Neoplasia, 2010, 12, 1031-IN22.	5.3	51
28	SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformationâ€“Specific Fusion Transcript in Prostate Cancer. Cancer Research, 2009, 69, 2734-2738.	0.9	181
29	AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. ELife, 0, 11, .	6.0	10